Informing on health and wellness news in Djibouti

Provided by AGP

Djibouti Health Journal
Got News to Share?
Got News to Share? Explore more publications!

Djibouti Health Journal: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Djibouti Health Journal.

March 2026

Mo Tu We Th Fr Sa Su
1
2 3 4 5 6 7 8
9 10 11 12 13 14 15
16 17 18 19 20 21 22
23 24 25 26 27 28 29
30 31

April 2026

Mo Tu We Th Fr Sa Su
1 2 3 4 5
6 7 8 9 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30

May 2026

Mo Tu We Th Fr Sa Su
1 2 3
4 5 6 7 8 9 10
11 12 13 14 15 16 17
18 19 20 21 22 23 24
25 26 27 28 29 30 31

Press releases published on April 9, 2026

Click Therapeutics and Boehringer Ingelheim Announce Series D Investment and Funding to Advance Commercialization of CT-155
Apr. 9, 2026

Click Therapeutics and Boehringer Ingelheim Announce Series D Investment and Funding to Advance Commercialization of CT-155

Indeterminate GlobeNewswire
Foghorn Therapeutics to Present New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and Selective CBP, EP300 and ARID1B Degrader Programs at the 2026 AACR Annual Meeting
Apr. 9, 2026

Foghorn Therapeutics to Present New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and Selective CBP, EP300 and ARID1B Degrader Programs at the 2026 AACR Annual Meeting

Indeterminate GlobeNewswire
Netramark-Authored, Peer-Reviewed Article Suggests Psychedelics Might Not Only Affect Brain Chemistry, They May Also Involve Quantum-Level Processes Inside the Brain
Apr. 9, 2026

Netramark-Authored, Peer-Reviewed Article Suggests Psychedelics Might Not Only Affect Brain Chemistry, They May Also Involve Quantum-Level Processes Inside the Brain

Indeterminate GlobeNewswire
Kymera Therapeutics Announces Gilead Sciences’ Option Exercise to License KT-200, Oral CDK2 Molecular Glue Degrader Development Candidate
Apr. 9, 2026

Kymera Therapeutics Announces Gilead Sciences’ Option Exercise to License KT-200, Oral CDK2 Molecular Glue Degrader Development Candidate

Indeterminate GlobeNewswire
Seres Therapeutics to Present at CARB-X Investor Day
Apr. 9, 2026

Seres Therapeutics to Present at CARB-X Investor Day

Indeterminate GlobeNewswire
Nkarta to Participate in Needham Virtual Healthcare Conference
Apr. 9, 2026

Nkarta to Participate in Needham Virtual Healthcare Conference

Indeterminate GlobeNewswire
Medicenna Therapeutics Appoints Dr. Nageatte Ibrahim as Chief Medical Officer
Apr. 9, 2026

Medicenna Therapeutics Appoints Dr. Nageatte Ibrahim as Chief Medical Officer

Indeterminate GlobeNewswire
C4 Therapeutics Expands Long-Term Partnership with Roche Through New Collaboration Agreement Focused on Discovering and Developing Degrader-Antibody Conjugates (DACs)
Apr. 9, 2026

C4 Therapeutics Expands Long-Term Partnership with Roche Through New Collaboration Agreement Focused on Discovering and Developing Degrader-Antibody Conjugates (DACs)

Indeterminate GlobeNewswire
Zymeworks Announces Additional Leadership Appointments to Advance Next Phase of Growth
Apr. 9, 2026

Zymeworks Announces Additional Leadership Appointments to Advance Next Phase of Growth

Indeterminate GlobeNewswire
Leads Biolabs’ Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Advances to Expansion Phase in First-Line Biliary Tract Cancer Following Positive Safety and Preliminary Efficacy Results
Apr. 9, 2026

Leads Biolabs’ Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Advances to Expansion Phase in First-Line Biliary Tract Cancer Following Positive Safety and Preliminary Efficacy Results

Indeterminate GlobeNewswire
Losing Your Voice? Millions Experience Persistent Problems Each Year
Apr. 9, 2026

Losing Your Voice? Millions Experience Persistent Problems Each Year

Indeterminate GlobeNewswire
Ecuador Free of Rabies project accelerates progress toward eliminating dog-mediated rabies supported by Boehringer Ingelheim’s Stop Rabies program
Apr. 9, 2026

Ecuador Free of Rabies project accelerates progress toward eliminating dog-mediated rabies supported by Boehringer Ingelheim’s Stop Rabies program

Indeterminate GlobeNewswire
Kainova Therapeutics Expands Phase I/II Trial of DT-7012, a Treg-depleting Anti-CCR8 Antibody, with First Patient Dosed in Europe
Apr. 9, 2026

Kainova Therapeutics Expands Phase I/II Trial of DT-7012, a Treg-depleting Anti-CCR8 Antibody, with First Patient Dosed in Europe

Indeterminate GlobeNewswire
Novartis announces expansion of community health programs to close gaps in heart disease and cancer care, targeting more than 30 countries by 2030
Apr. 9, 2026

Novartis announces expansion of community health programs to close gaps in heart disease and cancer care, targeting more than 30 countries by 2030

Indeterminate GlobeNewswire
Basilea erhält zusätzliche USD 6 Mio. von CARB-X für die klinische Entwicklung des Antibiotikums BAL2420
Apr. 9, 2026

Basilea erhält zusätzliche USD 6 Mio. von CARB-X für die klinische Entwicklung des Antibiotikums BAL2420

Indeterminate GlobeNewswire
Basilea awarded additional CARB-X funding of USD 6 million to support the clinical development of antibiotic BAL2420
Apr. 9, 2026

Basilea awarded additional CARB-X funding of USD 6 million to support the clinical development of antibiotic BAL2420

Indeterminate GlobeNewswire
New Peer-Reviewed Publication Highlights Evidence of Mother-to-Child-Transmission of Lyme Disease Bacteria During Pregnancy and Calls for Urgent Research
Apr. 9, 2026

New Peer-Reviewed Publication Highlights Evidence of Mother-to-Child-Transmission of Lyme Disease Bacteria During Pregnancy and Calls for Urgent Research

Indeterminate GlobeNewswire
HUTCHMED Highlights Data to be Presented at AACR Annual Meeting 2026
Apr. 9, 2026

HUTCHMED Highlights Data to be Presented at AACR Annual Meeting 2026

Indeterminate GlobeNewswire

Share us

on your social networks:
Facebook Facebook LinkedIn LinkedIn

Sign up for:

Djibouti Health Journal

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.